2020
Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancer
Malani R, Fleisher M, Kumthekar P, Lin X, Omuro A, Groves MD, Lin NU, Melisko M, Lassman AB, Jeyapalan S, Seidman A, Skakodub A, Boire A, DeAngelis LM, Rosenblum M, Raizer J, Pentsova E. Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancer. Journal Of Neuro-Oncology 2020, 148: 599-606. PMID: 32506369, PMCID: PMC7438284, DOI: 10.1007/s11060-020-03555-z.Peer-Reviewed Original ResearchConceptsLeptomeningeal metastasesCSF cytologyCSF CTCsCTC enumerationCerebrospinal fluidIT trastuzumabPhase I/II dose escalation trialCentral nervous system compartmentTumor cellsHER2/neu positivityHER2/neu expressionDose-escalation trialHER2-positive cancersIntrathecal trastuzumabEscalation trialRadiographic responseTumor burdenPositive cancersNeu expressionNeu positivityConclusionOur studyPatientsDay 1Epithelial cancersCancer
2019
Applications of artificial intelligence in neuro-oncology.
Aneja S, Chang E, Omuro A. Applications of artificial intelligence in neuro-oncology. Current Opinion In Neurology 2019, 32: 850-856. PMID: 31609739, DOI: 10.1097/wco.0000000000000761.Peer-Reviewed Original ResearchMeSH KeywordsArtificial IntelligenceBiomarkers, TumorBrain NeoplasmsGenomicsHumansMedical OncologyNeuroimagingNeurologyConceptsArtificial intelligenceArtificial intelligence algorithmsNatural language processingAmount of dataIntelligence algorithmsLanguage processingIntelligenceNeuro-oncologyImage analysisApplicationsAlgorithmRisk stratificationFuture innovationsTreatment responseBrain tumorsClinical practiceClassificationRecent applicationsProcessingSignificant promiseChallengesDetection
2018
In Vivo PET Assay of Tumor Glutamine Flux and Metabolism: In-Human Trial of 18F-(2S,4R)-4-Fluoroglutamine.
Dunphy MPS, Harding JJ, Venneti S, Zhang H, Burnazi EM, Bromberg J, Omuro AM, Hsieh JJ, Mellinghoff IK, Staton K, Pressl C, Beattie BJ, Zanzonico PB, Gerecitano JF, Kelsen DP, Weber W, Lyashchenko SK, Kung HF, Lewis JS. In Vivo PET Assay of Tumor Glutamine Flux and Metabolism: In-Human Trial of 18F-(2S,4R)-4-Fluoroglutamine. Radiology 2018, 287: 667-675. PMID: 29388903, PMCID: PMC5929369, DOI: 10.1148/radiol.2017162610.Peer-Reviewed Original ResearchConceptsPositron emission tomographyDifferent cancer typesCancer typesAcid levelsFisher's exact testAmino acid levelsInvestigational new drug applicationGlutamine metabolismInstitutional review boardFluorodeoxyglucose avidityAdult patientsIntravenous bolusAcute fastingAggressive tumorsClinical safetyPotential tumor biomarkerPET scansPatientsExact testHelsinki DeclarationDrug AdministrationNew drug applicationsEmission tomographyTumorsInformed consent
2017
Cerebrospinal fluid circulating tumor cells: a novel tool to diagnose leptomeningeal metastases from epithelial tumors
Lin X, Fleisher M, Rosenblum M, Lin O, Boire A, Briggs S, Bensman Y, Hurtado B, Shagabayeva L, DeAngelis LM, Panageas KS, Omuro A, Pentsova EI. Cerebrospinal fluid circulating tumor cells: a novel tool to diagnose leptomeningeal metastases from epithelial tumors. Neuro-Oncology 2017, 19: 1248-1254. PMID: 28821205, PMCID: PMC5570249, DOI: 10.1093/neuonc/nox066.Peer-Reviewed Original ResearchConceptsDiagnosis of LMLeptomeningeal metastasesCSF CTCsCSF cytologyEpithelial tumorsMRI findingsOptimal cutoffInstitutional review board-approved prospective studyTumor cellsNegative predictive value 97ROC analysisRare cell capture technologyPositive predictive value 90Positive CSF cytologyCSF of patientsSolid tumor patientsPrevious pilot studyClinical suspicionProspective studyCytology examinationTumor patientsLarge cohortCerebrospinal fluidPatientsStandard MRIMutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, Srinivasan P, Gao J, Chakravarty D, Devlin SM, Hellmann MD, Barron DA, Schram AM, Hameed M, Dogan S, Ross DS, Hechtman JF, DeLair DF, Yao J, Mandelker DL, Cheng DT, Chandramohan R, Mohanty AS, Ptashkin RN, Jayakumaran G, Prasad M, Syed MH, Rema AB, Liu ZY, Nafa K, Borsu L, Sadowska J, Casanova J, Bacares R, Kiecka IJ, Razumova A, Son JB, Stewart L, Baldi T, Mullaney KA, Al-Ahmadie H, Vakiani E, Abeshouse AA, Penson AV, Jonsson P, Camacho N, Chang MT, Won HH, Gross BE, Kundra R, Heins ZJ, Chen HW, Phillips S, Zhang H, Wang J, Ochoa A, Wills J, Eubank M, Thomas SB, Gardos SM, Reales DN, Galle J, Durany R, Cambria R, Abida W, Cercek A, Feldman DR, Gounder MM, Hakimi AA, Harding JJ, Iyer G, Janjigian YY, Jordan EJ, Kelly CM, Lowery MA, Morris LGT, Omuro AM, Raj N, Razavi P, Shoushtari AN, Shukla N, Soumerai TE, Varghese AM, Yaeger R, Coleman J, Bochner B, Riely GJ, Saltz LB, Scher HI, Sabbatini PJ, Robson ME, Klimstra DS, Taylor BS, Baselga J, Schultz N, Hyman DM, Arcila ME, Solit DB, Ladanyi M, Berger MF. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nature Medicine 2017, 23: 703-713. PMID: 28481359, PMCID: PMC5461196, DOI: 10.1038/nm.4333.Peer-Reviewed Original ResearchConceptsMemorial Sloan-Kettering Cancer CenterCancer-related genesProspective clinical sequencingAdvanced solid cancersSequencing platformsStructural variantsGenomic landscapeGenomic mutationsDetailed clinical annotationMutational landscapeSequencing resultsNumber alterationsCancer CenterPatient enrollmentClinical trialsMSK-IMPACTMetastatic cancerSolid cancersNew insightsNormal tissuesClinical sequencingCancer therapyPatientsCancerClinical annotation
2015
Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study
Butowski N, Colman H, De Groot JF, Omuro AM, Nayak L, Wen PY, Cloughesy TF, Marimuthu A, Haidar S, Perry A, Huse J, Phillips J, West BL, Nolop KB, Hsu HH, Ligon KL, Molinaro AM, Prados M. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro-Oncology 2015, 18: 557-564. PMID: 26449250, PMCID: PMC4799682, DOI: 10.1093/neuonc/nov245.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAminopyridinesBiomarkers, TumorBlood-Brain BarrierBrain NeoplasmsCohort StudiesFemaleFollow-Up StudiesGlioblastomaHumansImmunoenzyme TechniquesMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingPrognosisPyrrolesReceptors, Granulocyte-Macrophage Colony-Stimulating FactorTissue DistributionTumor BurdenConceptsPhase II studyII studyRecurrent glioblastomaTumor tissueMedian drug levelsPrimary efficacy endpointProgression-free survivalBlood-brain barrierPretreatment baseline valuesBlood-tumor barrierExploratory endpointsInhibitor PLX3397Efficacy endpointPrimary endpointSecondary endpointsObjective responseSurgical resectionOral dosePharmacodynamic changesPharmacodynamic measuresTumor burdenDrug exposureTissue pharmacokineticsDrug levelsStem cell factor
2013
Potential Role of Preoperative Conventional MRI Including Diffusion Measurements in Assessing Epidermal Growth Factor Receptor Gene Amplification Status in Patients with Glioblastoma
Young R, Gupta A, Shah A, Graber J, Schweitzer A, Prager A, Shi W, Zhang Z, Huse J, Omuro A. Potential Role of Preoperative Conventional MRI Including Diffusion Measurements in Assessing Epidermal Growth Factor Receptor Gene Amplification Status in Patients with Glioblastoma. American Journal Of Neuroradiology 2013, 34: 2271-2277. PMID: 23811973, PMCID: PMC4712068, DOI: 10.3174/ajnr.a3604.Peer-Reviewed Original ResearchAdolescentAdultAgedAged, 80 and overBiomarkers, TumorBrain NeoplasmsErbB ReceptorsFemaleGene AmplificationGlioblastomaHumansMagnetic Resonance ImagingMaleMiddle AgedMolecular ImagingPreoperative CarePrognosisReproducibility of ResultsSensitivity and SpecificityTissue DistributionUp-RegulationYoung Adult
2011
Continuing the search for MR imaging biomarkers for MGMT promoter methylation status: conventional and perfusion MRI revisited
Gupta A, Omuro AM, Shah AD, Graber JJ, Shi W, Zhang Z, Young RJ. Continuing the search for MR imaging biomarkers for MGMT promoter methylation status: conventional and perfusion MRI revisited. Neuroradiology 2011, 54: 641-643. PMID: 22006425, PMCID: PMC4724213, DOI: 10.1007/s00234-011-0970-z.Peer-Reviewed Original Research
2007
Molecular genetic markers as predictors of response to chemotherapy in gliomas
Idbaih A, Omuro A, Ducray F, Hoang-Xuan K. Molecular genetic markers as predictors of response to chemotherapy in gliomas. Current Opinion In Oncology 2007, 19: 606-611. PMID: 17906460, DOI: 10.1097/cco.0b013e3282f075f3.Peer-Reviewed Original ResearchConceptsAnaplastic oligodendroglial tumorsLow-grade gliomasProspective trialMGMT statusOligodendroglial tumorsIndependent favorable prognostic factorFavorable prognostic factorRelevant prognostic markerPredictors of responsePromoter methylationTreatment of gliomaPredictor of chemosensitivityMGMT promoter methylationObjective responsePrognostic factorsRetrospective studyPrognostic markerSuch tumorsTreatment decisionsChromosome 1p/19q codeletionMGMT inactivationPredictive valueChemotherapyGliomasLow expression